Pre-RA Pharmacological Interventions: Delaying is not Enough Dr. Aurelie Najm reports on both the Great Debate as well as abstracts 0530, 1603 at #ACR22 https://t.co/n8hzJMpmWO https://t.co/8OISSK34No

• https://bit.ly/3Upuz1c

The complexity of opioid use in spondyloarthritis A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. https://t.co/B4Q7Af7doF https://t.co/sdjHoa8shP

• https://bit.ly/3GZTeq1

ACR22: Polymyalgia Rheumatica in the Spotlight One of the enduring legacies of #ACR22 for Dr. Putman ( @EBRheum) will be the emphasis on PMR. Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run. https://t.co/SYKT3a03Tc https://t.co/9CIRp66vSK

• https://bit.ly/3FfWPPH

Estimated Global SLE market size was $1.46 billion in 2020, with a global (7 Major countries) prevalence of 651,965 in 2020; and a USA prevalence of 351,176 SLE cases. https://t.co/f4Tghup5PC https://t.co/p1w9KFQR4z

• https://bit.ly/3UgHrGR

1602 pemphigus pts Rx w/ rituximab vs azathioprine or MMF. RTX pts had lower risk of MI (RR 0.45; P = .01), CVA (RR, 0.42; P < .001), PVD (0.47), HTN (0.48), hyperlipidemia (0.45), NIDDM (0.63), obesity (0.49). Mortality equal betw groups https://t.co/uvDDU5z8gp https://t.co/kJAg5xRKHz

• https://bit.ly/3OXeEGn

Etoricoxib and Celecoxib may lower CVA risk. Taiwanese study of 10,857 newly Dx RA pts. Coxib use vs non-use compared re: future CVA. Celecoxib pts had reduced CVA (HR 0.67 @200/d; HR 0.22 if <3.5 yrs). Etoricoxib also (HR 0.35; 0.16–0.80) https://t.co/GQEp8N0uZb https://t.co/TxfyIemzBT

• https://bit.ly/3VGxxPU

NRMP Results for rheumatology 2022 : - Adult Rheum: 97.8% of 272 fellow positions filled (41% US grads) (371 applied) - Pediatric Rheum: 69.2% of 39 positions filled (54% US grads) (29 applied) WE NEED MORE ADULT PROGRAMS AND MORE INTEREST IN PEDI RHEUM https://t.co/YpMhTPnDM4 https://t.co/Aa3EV57yij

• https://bit.ly/3VMn5GR

AURORA1 RCT 📍Efficacy of voclosporin in LN III-V with UPC > 1.5g 💊VOC 23.7 mg BID vs. PCB 💊All got MMF 1g BID and GC 🥇#1 outcome: UPC < 0.5, stable 🫘 fx, ❌ GC > 10 mg -40% VOC v. 23% PCB (sig) -all measures favored VOC, but only sig. for UPC < 0.5

Topic Podcasts - JAK TYK2 https://t.co/DqfEj955aw https://t.co/HRj28berzF

• https://bit.ly/3gFJMh3

A great read from Dr. Anthony Fauci as he steps down from leading the NIH NIAID research for nearly 40 years. He writes on pundits, need for specialty growth, evolution of vaccines and "it aint over till its over" is now "its never over" https://t.co/z0noGckIvx https://t.co/DJKG88V1mc

• https://bit.ly/3Hh8rn5

Estimated worldwide market for DMARDs in 2022 was $20.7 billion USD and is expected to rise at a 3.5% annual growth rate to $ 272 billion USD by 2030 https://t.co/futp7249rF https://t.co/QgxJR7TQNw

• https://bit.ly/3ueAYle

The Great Debate: To Treat or Not to Treat Pre RA Dr. Janet Pope ( @Janetbirdope) and Dr. Jonathan Kay ( @RheumKay) discuss the Great Debate, which Dr. Pope participated in, at #ACR22. https://t.co/PPXiX8MG6m https://t.co/Uy0kQd7XGz

• https://bit.ly/3Fe65nw